recombinant activated Factor VII
GPTKB entity
Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:protein
gptkb:drug |
| gptkbp:administeredBy |
intravenous injection
|
| gptkbp:approvedBy |
gptkb:FDA
1999 |
| gptkbp:ATCCode |
B02BD08
|
| gptkbp:brand |
NovoSeven
Sevenfact |
| gptkbp:contraindication |
hypersensitivity to active substance
|
| gptkbp:discoveredBy |
gptkb:Novo_Nordisk
|
| gptkbp:halfLife |
2-3 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
recombinant activated Factor VII
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
activates the extrinsic pathway of coagulation cascade
|
| gptkbp:molecularWeight |
50 kDa
|
| gptkbp:producedBy |
recombinant DNA technology
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
rash allergic reactions thromboembolic events |
| gptkbp:usedFor |
gptkb:hemophilia_B
gptkb:hemophilia_A gptkb:acquired_hemophilia Glanzmann's thrombasthenia congenital Factor VII deficiency treatment of bleeding episodes |
| gptkbp:bfsParent |
gptkb:Factor_VIIa
|
| gptkbp:bfsLayer |
7
|